Invoking MCP tool get_variant_evidence with input {"diseaseName":"Follicular Lymphoma","therapyName":"Venetoclax","significance":"RESISTANCE"}
MCP tool get_variant_evidence returned meta=None content=[TextContent(type='text', text='{
  "Field Descriptions": "evidenceType: Category describing the type of clinical or biological evidence (e.g., predictive, diagnostic).\
evidenceDirection: Indicates whether the evidence supports or refutes the association.\
significance: The clinical relevance of the evidence.\
description: Detailed summary of the evidence from CIViC curators.\
evidenceLevel: Describes the robustness of the study type. A - Validated association, B - Clinical evidence, C - Case study, D - Preclinical evidence, and E - Inferential association\
evidenceRating: Quality score assigned to the evidence by curators (scored 1-5).\
url: Direct link to the CIViC record for this evidence item.\
When returning information to users you MUST cite URLs used for specific information.",
  "API Results": [
    {
      "status": "ACCEPTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "F104I",
            "feature": {
              "name": "BCL2"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Follicular Lymphoma"
      },
      "therapies": [
        {
          "name": "Venetoclax"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.",
      "evidenceLevel": "C",
      "evidenceRating": 2,
      "url": "https://identifiers.org/civic.eid:8375"
    },
    {
      "status": "ACCEPTED",
      "evidenceType": "PREDICTIVE",
      "evidenceDirection": "SUPPORTS",
      "significance": "RESISTANCE",
      "molecularProfile": {
        "variants": [
          {
            "name": "F104I",
            "feature": {
              "name": "BCL2"
            }
          }
        ]
      },
      "disease": {
        "displayName": "Follicular Lymphoma"
      },
      "therapies": [
        {
          "name": "Venetoclax"
        }
      ],
      "variantOrigin": "SOMATIC",
      "description": "Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.",
      "evidenceLevel": "D",
      "evidenceRating": 3,
      "url": "https://identifiers.org/civic.eid:8376"
    }
  ]
}', annotations=None, meta=None)] structuredContent=None isError=False
### LLM OUTPUT ###
BCL2
